[Immunoglobulin therapy of primary humoral immunologic deficiencies].
There is a strong body of evidence documenting that immunoglobulin therapy reduces the incidence and severity of infections in patients with primary humoral immunodeficiencies, whatever patient's age. Health-related quality of life is significantly improved in particular by self-infusions of subcutaneous immunoglobulins. Residual levels of total IgG over 6-800 mg/dL may help prevent progression of lung damage. Levels of IgG, clinical manifestations, pulmonary function tests and high resolution computed tomography routine surveillance is recommended.
Bordigoni
Pierre
P
Département d'hémato-oncologie pédiatrique et de transplantation médullaire, hôpital d'enfants de Brabois, CHU de Nancy, 54511 Vandoeuvre-lès-Nancy. p.bordigoni@chu-nancy.fr
D058186:Acute Kidney Injury / Q000209:etiology; D000328:Adult; D000361:Agammaglobulinemia / Q000188:drug therapy* / Q000276:immunology; D000707:Anaphylaxis / Q000209:etiology; D002648:Child; D017074:Common Variable Immunodeficiency / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000627:therapeutic use; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D011788:Quality of Life
D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors